2021 年欧洲造血细胞移植和细胞治疗：SARS-CoV-2 大流行第二年——来自 EBMT 活动调查的报告

In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 patients received advanced cellular therapies, 2524 of which were CAR-T treatments, an additional 3245 received DLI. Changes compared to the previous year were CAR-T treatment (+35%), allogeneic HCT +5. 4%, autologous HCT +3. 9%, more pronounced in non-malignant disorders. Main indications for allogeneic HCT were myeloid malignancies 10,745 (58%), lymphoid malignancies 5127 (28%) and non-malignant disorders 2501 (13%). Main indications for autologous HCT were lymphoid malignancies 22,129 (90%) and solid tumors 1635 (7%).

In allogeneic HCT, use of haploidentical donors decreased by -0. 9% while use of unrelated and sibling donors increased by +4. 3% and +9%. Cord blood HCT decreased by -5. 8%. Pediatric HCT increased overall by +5. 6% (+6. 9% allogeneic and +1. 6% autologous). Increase in the use of CAR-T was mainly restricted to high-income countries.

The drop in HCT activity reported in 2020 partially recovered in 2021, the second year of the SARS-CoV-2 pandemic. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual EBMT report reflects current activities useful for health care resource planning.